The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
Sophie B. Willemse(Amsterdam UMC Location University of Amsterdam), Homie Razavi(Center for Disease Analysis), J. Marleen de Vree(University of Groningen), Maria Prins(University of Amsterdam), H.W. Reesink(University of Amsterdam), Devin Razavi‐Shearer(University of Health Sciences Antigua), Irene Veldhuijzen(GGD Rotterdam-Rijnmond), Daniela K van Santen(Burnet Institute), Esther A. Croes(Trimbos Institute), Robert J. de Knegt(Erasmus MC), Hans L. Zaaijer(Sanquin), Freke Zuure(University of Amsterdam)
PubMed
November 1, 2015
Cited by 20
Related Papers
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study
|Clinical Infectious Diseases|2014|773
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484